Meeting
2016 Genitourinary Cancers Symposium
Intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT): A risk group with heterogeneous behavior.
Authors
Constanza Pérez de la Puente
Instituto Alexander Fleming, Buenos Aires, Argentina
Constanza Pérez de la Puente , Federico Losco , Carolina Chacon , Juan Pablo Sade , Gonzalo H. Giornelli , Matias Chacon , Reinaldo D. Chacon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 145)
DOI
10.1200/jco.2016.34.2_suppl.145
Abstract #
145
Poster Bd #
C4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).
First Author: Guilhem Roubaud
Poster
2020 Genitourinary Cancers Symposium
INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.
First Author: Martin T. King
Poster
2018 Genitourinary Cancers Symposium
A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.
First Author: Melvin Chua
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
First Author: Zin Myint